Rosuvastatin to Decrease Residual Immune Activation in HIV Infection
Status:
Unknown status
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
Participating countries: France Objectives Principal objective To evaluate, in HIV-1 infected
patients receiving effective antiretroviral therapy, the effect of the addition of
Rosuvastatin (dose of 20mg/day) for 3 months, on CD8 T cell activation as assessed by the
proportion of peripheral CD8 T cells that co-express the activation markers CD38 and HLA-DR
Secondary objectives To evaluate the effect of Rosuvastatin administration on residual CD4
and CD8 T cell activation To evaluate the effect of Rosuvastatin administration on the main
serum soluble biomarkers of activation (CRP- HS, D-dimers, IL-6 and soluble CD14) To evaluate
the effect of Rosuvastatin administration on CD4 T-cell count and on the CD4/CD8 T-cell ratio
To study the relationship between the level of immune activation and the level of residual
HIV replication in plasma To study the effect of Rosuvastatin administration on lipid
profiles and the correlation between the HDL cholesterol and the CD4/CD8 T-cell ratio To
evaluate the tolerance of Rosuvastatin at the dose of 20 mg/day
Phase:
Phase 2
Details
Lead Sponsor:
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba